# Mysthera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mysthera-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Total disclosed funding: $3.5M
- Latest round: Seed (Aug 21, 2023)
- Investors on record: 1

## About

Based in Basel, Switzerland, and founded in 2023, Mysthera Therapeutics AG operates as a developer of therapeutics to treat autoimmune diseases, including glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. As of 2023, the company is led by its CEO, Darren Cunningham. In August 2023, Mysthera Therapeutics AG raised USD 3.5 million in seed funding from investor Forty51 Ventures. 

The company is developing oral treatments for complex autoimmune diseases using PIM kinase inhibitors. These inhibitors target immune cell-related autoimmune disorders of different types. Their approach aims to balance the immune system without completely suppressing it, a challenge that current therapies haven't fully solved. Tertiary lymphoid structures (TLS), which are abnormal clusters of immune cells, play a crucial role. These structures form in tissues during long-term inflammation and are common in diseases like lupus nephritis, rheumatoid arthritis, and inflammatory bowel disease. The interactions between activated T and B cells triggered by CD40L-CD40 and STAT3 signalling cytokines lead to their formation. 

The company plans to use August 2023 funding to progress its collection of pre-clinical stage pan-PIM kinase inhibitors. These inhibitors are intended to distinctly regulate the functions of immune cells across various lineages.

## Funding rounds

- Seed, Aug 21, 2023, $3.5M — Forty51 Ventures

## Investors

- Forty51 Ventures (https://capitalatlas.ai/funds/forty51-ventures) — Seed